The DOI matches its Crossref record, with a small difference in title or year; 1,376 of the 1,396 references it cites were found in a registry or an index.
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
Open accessAbstract
AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation” provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. STRUCTURE Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the “2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” and the “2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lifestyle modification is not only effective for supporting moderate weight loss (5% to 10% of weight), but it also has favorable effects on multiple metabolic risk factors, even independent of weight loss.8–11”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Components should include dietary changes to promote a calorie deficit of 500 to 750 kcal/day, ≥150 minutes per week of moderately vigorous aerobic activity, and ≥14 months of behavioral therapy, including self-monitoring of dietary intake, physical activity, and weight, and guided problem solving.9,10”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The AHA/ACC and several societies recommend intensive, multicomponent behavioral weight loss interventions led by clinicians having the ability to successfully initiate weight loss counseling.9–11”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, habitual physical activity, including activities that reduce sedentary time, aerobic physical activity, and resistance training, are associated with improvements in several CKM risk factors (HbA1c, waist circumference, fat percentage, BP) and mortality.5–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A heart-healthy diet and regular physical activity remain the cornerstones of therapy in patients with T2D and ASCVD, with demonstrated benefits for CKM risk profiles.5–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Small lifestyle intervention trials suggest weight loss efficacy and safety in HFrEF,8–10”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among patients with kidney failure (end-stage kidney disease) receiving dialysis, CVD rates are high and the leading cause of death, with unique CVD phenotypes.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Screening caregivers of youth populations for SDOH identifies childhood exposures to social factors that can influence CKM health across the life course.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Additionally, comorbid conditions such as CVD and obstructive sleep apnea (OSA) do not interfere with the success of weight loss in several studies.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Among patients who have undergone MBS and have regained a significant amount of weight (≥25% or more of total lost weight), GLP-1–based therapies can be useful in promoting weight loss and management of comorbidities.9–13”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (LSG) comprise 90% of all procedures.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The oral formulation appears slightly less efficacious than the subcutaneous version for facilitating weight loss.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This translated into a number needed to treat of 49 over 3 years to prevent 1 HF event.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although other measures of atherosclerosis (eg, ankle brachial index, carotid intima media thickness) have shown utility in risk assessment,9–11 studies have been limited in demonstrating their utility for guiding clinical care.”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the only dedicated GLP-1 RA trial of patients with diabetes and albuminuric CKD (FLOW), semaglutide demonstrated a significant reduction in HF events in the overall sample (HR, 0.74 [95% CI, 0.58–0.94]) with similar reduction in incident HF among those without baseline HF (HR, 0.68 [95% CI, 0.50–0.91]).8,9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Nonrandomized reports across a spectrum of HF (ambulatory patients with chronic HF, a new HF diagnosis, and individuals with a recent hospitalization) and a variety of ages do not support harm with metformin therapy, though metformin is contraindicated in decompensated HF.9,30”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“though metformin is contraindicated in decompensated HF.9,30”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Initiation of SGLT2i is efficacious in reducing risk of the outcomes of cardiovascular mortality, HF hospitalization, and decline in eGFR for patients with stage 4 CKM with CKD (GFR >20 mL/min/1.73 m2) and HFrEF, particularly for those with albuminuria.9–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“but data are more sparse in patients with severely decreased kidney disease (stage G4 CKD), and the presence/absence of albuminuria is understudied in HF trials.9–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SGLT2i initiation have demonstrated efficacy among patients with eGFR >20 mL/min/1.73 m2 and HFmrEF/HFpEF in reducing composite cardiovascular mortality and HF hospitalizations, but data are more sparse in patients with severely decreased kidney disease (stage G4 CKD), and the presence/absence of albuminuria is understudied in HF trials.9–12”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In a substudy of the randomized, open-label, parallel-group, Phase III SURPASS-3 trial, tirzepatide, a GLP-1/GIP receptor agonist approved for treatment of T2D, compared to insulin degludec, significantly reduced liver fat content among persons with T2D.9”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“GLP-1–based therapy can be an effective adjunctive treatment to achieve weight loss goals in MASLD, with additional favorable effects on liver histology as discussed below.8,9,42”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Meta-analyses and cohort studies have found that women with CKD are at increased risk of APOs.9–11,39”
From 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome (2026) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
Self-citationRivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationApixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.
Haïssaguerre, M., Jaïs, P., Shah, D. C., Takahashi, A., Hocini, M., Quiniou, G., Garrigue, S., Mouroux, A. L., Métayer, P. L., & Clémenty, J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809033391003 · Cited by 8,040
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051
Research works printed but not linked: 246
- Schnabel, 2015, 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study, Lancet, 386, 154, 10.1016/S0140-6736(14)61774-8 · DOI · Paper page
- Mou, 2018, Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC study (Atherosclerosis Risk in Communities), Circ Arrhythm Electrophysiol, 11, 10.1161/CIRCEP.118.006350 · DOI
- Haissaguerre, 1998, Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins, N Engl J Med, 339, 659, 10.1056/NEJM199809033391003 · DOI
- Haissaguerre, 1998, Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins, N Engl J Med, 339, 659, 10.1056/NEJM199809033391003 · DOI
- Voigt, 2010, Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation, Circ Arrhythm Electrophysiol, 3, 472, 10.1161/CIRCEP.110.954636 · DOI
- Lubitz, 2010, Association between familial atrial fibrillation and risk of new-onset atrial fibrillation, JAMA, 304, 2263, 10.1001/jama.2010.1690 · DOI · Paper page
- Roselli, 2018, Multi-ethnic genome-wide association study for atrial fibrillation, Nat Genet, 50, 1225, 10.1038/s41588-018-0133-9 · DOI
- Lunde, 2018, Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review, Expert Rev Cardiovasc Ther, 16, 857, 10.1080/14779072.2018.1533118 · DOI
- Kunneman, 2020, Assessment of shared decision-making for stroke prevention in patients with atrial fibrillation: a randomized clinical trial, JAMA Intern Med, 180, 1215, 10.1001/jamainternmed.2020.2908 · DOI
- Alonso, 2013, Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium, J Am Heart Assoc, 2
- Shang, 2016, Chronic kidney disease and the risk of new-onset atrial fibrillation: a meta-analysis of prospective cohort studies, PLoS One, 11, 10.1371/journal.pone.0155581 · DOI
- Perez, 2019, Large-scale assessment of a smartwatch to identify atrial fibrillation, N Engl J Med, 381, 1909, 10.1056/NEJMoa1901183 · DOI · Paper page
- Aune, 2018, Tobacco smoking and the risk of atrial fibrillation: a systematic review and meta-analysis of prospective studies, Eur J Prev Cardiol, 25, 1437, 10.1177/2047487318780435 · DOI
- Aune, 2018, Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies, J Diabetes Complications, 32, 501, 10.1016/j.jdiacomp.2018.02.004 · DOI
- Soliman, 2020, Effect of intensive blood pressure lowering on the risk of atrial fibrillation, Hypertension, 75, 1491, 10.1161/HYPERTENSIONAHA.120.14766 · DOI
- Alonso, 2013, Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium, J Am Heart Assoc, 2
- Himmelreich, 2020, Prediction models for atrial fibrillation applicable in the community: a systematic review and meta-analysis, Europace, 22, 684, 10.1093/europace/euaa005 · DOI
- Roselli, 2018, Multi-ethnic genome-wide association study for atrial fibrillation, Nat Genet, 50, 1225, 10.1038/s41588-018-0133-9 · DOI
- Huxley, 2011, Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study, Circulation, 123, 1501, 10.1161/CIRCULATIONAHA.110.009035 · DOI · Paper page
- Mishima, 2021, Self-reported physical activity and atrial fibrillation risk: a systematic review and meta-analysis, Heart Rhythm, 18, 520, 10.1016/j.hrthm.2020.12.017 · DOI
- Newman, 2021, Risk of atrial fibrillation in athletes: a systematic review and meta-analysis, Br J Sports Med, 55, 1233, 10.1136/bjsports-2021-103994 · DOI · Paper page
- Marcus, 2021, Acute consumption of alcohol and discrete atrial fibrillation events, Ann Intern Med, 174, 1503, 10.7326/M21-0228 · DOI
- Lu, 2021, Genetically determined tobacco and alcohol use and risk of atrial fibrillation, BMC Med Genomics, 14, 73, 10.1186/s12920-021-00915-0 · DOI
- Abed, 2013, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial, JAMA, 310, 2050, 10.1001/jama.2013.280521 · DOI · Paper page
- Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
- Middeldorp, 2018, PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study, Europace, 20, 1929, 10.1093/europace/euy117 · DOI
- Di Benedetto, 2018, Individual and combined impact of lifestyle factors on atrial fibrillation in apparently healthy men and women: the EPIC-Norfolk prospective population study, Eur J Prev Cardiol, 25, 1374, 10.1177/2047487318782379 · DOI
- Donnellan, 2019, Outcomes of atrial fibrillation ablation in morbidly obese patients following bariatric surgery compared with a nonobese cohort, Circ Arrhythm Electrophysiol, 12, 10.1161/CIRCEP.119.007598 · DOI
- Donnellan, 2019, Association between pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly obese patients undergoing atrial fibrillation ablation, Europace, 21, 1476, 10.1093/europace/euz183 · DOI
- Donnellan, 2020, Impact of bariatric surgery on atrial fibrillation type, Circ Arrhythm Electrophysiol, 13, 10.1161/CIRCEP.119.007626 · DOI
- Mohanty, 2018, Impact of weight loss on ablation outcome in obese patients with longstanding persistent atrial fibrillation, J Cardiovasc Electrophysiol, 29, 246, 10.1111/jce.13394 · DOI
- Hegbom, 2007, Effects of short-term exercise training on symptoms and quality of life in patients with chronic atrial fibrillation, Int J Cardiol, 116, 86, 10.1016/j.ijcard.2006.03.034 · DOI
- Malmo, 2016, Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial, Circulation, 133, 466, 10.1161/CIRCULATIONAHA.115.018220 · DOI · Paper page
- Elliott, 2023, An exercise and physical activity program in patients with atrial fibrillation: the ACTIVE-AF randomized controlled trial, J Am Coll Cardiol EP, 9, 455
- Pathak, 2015, Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study, J Am Coll Cardiol, 66, 985, 10.1016/j.jacc.2015.06.488 · DOI · Paper page
- Oesterle, 2022, Effects of supervised exercise training on atrial fibrillation: a meta-analysis of randomized controlled trials, J Cardiopulm Rehabil Prev, 42, 258, 10.1097/HCR.0000000000000665 · DOI
- Osbak, 2011, A randomized study of the effects of exercise training on patients with atrial fibrillation, Am Heart J, 162, 1080, 10.1016/j.ahj.2011.09.013 · DOI
- Andersen, 2013, Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study, Eur Heart J, 34, 3624, 10.1093/eurheartj/eht188 · DOI · Paper page
- Arnett, 2019, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 74, e177, 10.1016/j.jacc.2019.03.010 · DOI · Paper page
- Voskoboinik, 2020, Alcohol abstinence in drinkers with atrial fibrillation, N Engl J Med, 382, 20, 10.1056/NEJMoa1817591 · DOI
- Marcus, 2022, Individualized studies of triggers of paroxysmal atrial fibrillation: the I-STOP-AFib randomized clinical trial, JAMA Cardiol, 7, 167, 10.1001/jamacardio.2021.5010 · DOI
- Marcus, 2021, Acute consumption of alcohol and discrete atrial fibrillation events, Ann Intern Med, 174, 1503, 10.7326/M21-0228 · DOI
- Abed, 2013, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial, JAMA, 310, 2050, 10.1001/jama.2013.280521 · DOI · Paper page
- Pathak, 2014, Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study, J Am Coll Cardiol, 64, 2222, 10.1016/j.jacc.2014.09.028 · DOI · Paper page
- Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
- Middeldorp, 2018, PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study, Europace, 20, 1929, 10.1093/europace/euy117 · DOI
- Marcus, 2022, Individualized Studies of triggers of paroxysmal atrial fibrillation: the I-STOP-AFib randomized clinical trial, JAMA Cardiol, 7, 167, 10.1001/jamacardio.2021.5010 · DOI
- Abed, 2013, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial, JAMA, 310, 2050, 10.1001/jama.2013.280521 · DOI · Paper page
- Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
- Donnellan, 2019, Association between pre-ablation glycemic control and outcomes among patients with diabetes undergoing atrial fibrillation ablation, J Am Coll Cardiol EP, 5, 897
- Neefs, 2017, Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis, Int J Cardiol, 231, 155, 10.1016/j.ijcard.2016.12.029 · DOI · Paper page
- Steinberg, 2020, Effect of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension: the ERADICATE-AF randomized clinical trial, JAMA, 323, 248, 10.1001/jama.2019.21187 · DOI · Paper page
- Pathak, 2014, Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study, J Am Coll Cardiol, 64, 2222, 10.1016/j.jacc.2014.09.028 · DOI · Paper page
- Pinho-Gomes, 2021, Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: an individual participant data meta-analysis, PLoS Med, 18, 10.1371/journal.pmed.1003599 · DOI
- Parkash, 2017, Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control]), Circulation, 135, 1788, 10.1161/CIRCULATIONAHA.116.026230 · DOI · Paper page
- Soliman, 2020, Effect of intensive blood pressure lowering on the risk of atrial fibrillation, Hypertension, 75, 1491, 10.1161/HYPERTENSIONAHA.120.14766 · DOI
- Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
- Li, 2021, Effects of continuous positive airway pressure treatment in obstructive sleep apnea patients with atrial fibrillation: a meta-analysis, Medicine (Baltimore), 100
- Yang, 2020, CPAP is associated with decreased risk of AF recurrence in patients with OSA, especially those younger and slimmer: a meta-analysis, J Interv Card Electrophysiol, 58, 369, 10.1007/s10840-020-00738-6 · DOI
- Congrete, 2018, Effect of obstructive sleep apnea and its treatment of atrial fibrillation recurrence after radiofrequency catheter ablation: a meta-analysis, J Evid Based Med, 11, 145, 10.1111/jebm.12313 · DOI
- Deng, 2018, Treating obstructive sleep apnea with continuous positive airway pressure reduces risk of recurrent atrial fibrillation after catheter ablation: a meta-analysis, Sleep Med, 46, 5, 10.1016/j.sleep.2018.02.013 · DOI
- Qureshi, 2015, Meta-analysis of continuous positive airway pressure as a therapy of atrial fibrillation in obstructive sleep apnea, Am J Cardiol, 116, 1767, 10.1016/j.amjcard.2015.08.046 · DOI
- Szymanski, 2015, Presence and severity of obstructive sleep apnea and remote outcomes of atrial fibrillation ablations - a long-term prospective, cross-sectional cohort study, Sleep Breath, 19, 849, 10.1007/s11325-014-1102-x · DOI · Paper page
- Caples, 2019, The impact of continuous positive airway pressure treatment on the recurrence of atrial fibrillation post cardioversion: a randomized controlled trial, Int J Cardiol, 278, 133, 10.1016/j.ijcard.2018.11.100 · DOI · Paper page
- Traaen, 2021, Effect of continuous positive airway pressure on arrhythmia in atrial fibrillation and sleep apnea: a randomized controlled trial, Am J Respir Crit Care Med, 204, 573, 10.1164/rccm.202011-4133OC · DOI
- Hunt, 2022, Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: a randomized controlled trial, Heart Rhythm, 19, 1433, 10.1016/j.hrthm.2022.06.016 · DOI
- Voskoboinik, 2020, Alcohol abstinence in drinkers with atrial fibrillation, N Engl J Med, 382, 20, 10.1056/NEJMoa1817591 · DOI
- Abed, 2013, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial, JAMA, 310, 2050, 10.1001/jama.2013.280521 · DOI · Paper page
- Rienstra, 2018, Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial, Eur Heart J, 39, 2987, 10.1093/eurheartj/ehx739 · DOI · Paper page
- Hlatky, 2009, Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association, Circulation, 119, 2408, 10.1161/CIRCULATIONAHA.109.192278 · DOI
- Rao, 2015, Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, J Am Heart Assoc, 4
- Steinberg, 2015, Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial, Eur Heart J, 36, 288, 10.1093/eurheartj/ehu359 · DOI
- Chao, 2018, Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors, Thromb Haemost, 118, 768, 10.1055/s-0038-1636534 · DOI
- Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 · DOI · Paper page
- Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 · DOI · Paper page
- Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 · DOI · Paper page
- Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 · DOI · Paper page
- Singer, 2013, A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score, J Am Heart Assoc, 2
- Gage, 2001, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, JAMA, 285, 2864, 10.1001/jama.285.22.2864 · DOI · Paper page
- Buck, 2021, Effect of implantable vs prolonged external electrocardiographic monitoring on atrial fibrillation detection in patients with ischemic stroke: the per diem randomized clinical trial, JAMA, 325, 2160, 10.1001/jama.2021.6128 · DOI
- Eckman, 2011, Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation, Circ Cardiovasc Qual Outcomes, 4, 14, 10.1161/CIRCOUTCOMES.110.958108 · DOI
- Gutiérrez, 2020, Beneficial effect of left atrial appendage closure during cardiac surgery: a meta-analysis of 280 585 patients, Eur J Cardiothorac Surg, 57, 252
- Holmes, 2014, Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial, J Am Coll Cardiol, 64, 1, 10.1016/j.jacc.2014.04.029 · DOI
- Reddy, 2017, 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials, J Am Coll Cardiol, 70, 2964, 10.1016/j.jacc.2017.10.021 · DOI
- Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 · DOI · Paper page
- Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 · DOI · Paper page
- Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 · DOI · Paper page
- Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 · DOI · Paper page
- Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 · DOI · Paper page
- López-López, 2017, Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis, BMJ, 359, j5058, 10.1136/bmj.j5058 · DOI
- Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0 · DOI · Paper page
- Brokmeier, 2021, Off-label use for direct oral anticoagulants: valvular atrial fibrillation, heart failure, left ventricular thrombus, superficial vein thrombosis, pulmonary hypertension-a systematic review, Ann Pharmacother, 55, 995, 10.1177/1060028020970618 · DOI
- Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007 · DOI · Paper page
- Sanna, 2014, Cryptogenic stroke and underlying atrial fibrillation, N Engl J Med, 370, 2478, 10.1056/NEJMoa1313600 · DOI · Paper page
- Kirchhof, 2020, Early rhythm-control therapy in patients with atrial fibrillation, N Engl J Med, 383, 1305, 10.1056/NEJMoa2019422 · DOI
- Van Gelder, 2010, Lenient versus strict rate control in patients with atrial fibrillation, N Engl J Med, 362, 1363, 10.1056/NEJMoa1001337 · DOI · Paper page
- Connolly, 2011, Dronedarone in high-risk permanent atrial fibrillation, N Engl J Med, 365, 2268, 10.1056/NEJMoa1109867 · DOI
- Ulimoen, 2013, Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation, Am J Cardiol, 111, 225, 10.1016/j.amjcard.2012.09.020 · DOI · Paper page
- Nikolaidou, 2009, Chronic atrial fibrillation: a systematic review of medical heart rate control management, Postgrad Med J, 85, 303, 10.1136/pgmj.2008.068908 · DOI · Paper page
- Hohnloser, 2009, Effect of dronedarone on cardiovascular events in atrial fibrillation, Revista Portuguesa de Cardiologia, 28, 345
- Brignole, 1998, Atrioventricular junction ablation and pacemaker therapy versus drug treatment in atrial fibrillation, Cardiol Rev, 15, 49
- D, 2009, Survival of dual chamber pacing post atrioventricular nodal ablation in patients with atrial fibrillation, Heart Rhythm, 6, S406
- Santhanakrishnan, 2016, Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction, Circulation, 133, 484, 10.1161/CIRCULATIONAHA.115.018614 · DOI
- Van Gelder, 2010, Lenient versus strict rate control in patients with atrial fibrillation, N Engl J Med, 362, 1363, 10.1056/NEJMoa1001337 · DOI · Paper page
- Andrade, 2021, Cryoablation or drug therapy for initial treatment of atrial fibrillation, N Engl J Med, 384, 305, 10.1056/NEJMoa2029980 · DOI
- Kirchhof, 2020, Early rhythm-control therapy in patients with atrial fibrillation, N Engl J Med, 383, 1305, 10.1056/NEJMoa2019422 · DOI
- Kim, 2021, Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study, BMJ, 373, n991, 10.1136/bmj.n991 · DOI
- Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002 · DOI · Paper page
- Hsu, 2004, Catheter ablation for atrial fibrillation in congestive heart failure, N Engl J Med, 351, 2373, 10.1056/NEJMoa041018 · DOI
- Aryana, 2015, Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization, Heart Rhythm, 12, 1431, 10.1016/j.hrthm.2015.03.028 · DOI · Paper page
- Boersma, 2017, Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial, Heart Rhythm, 14, 1302, 10.1016/j.hrthm.2017.05.038 · DOI
- Lip, 2014, Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study), Am J Cardiol, 113, 480, 10.1016/j.amjcard.2013.10.036 · DOI
- Airaksinen, 2013, Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study, J Am Coll Cardiol, 62, 1187, 10.1016/j.jacc.2013.04.089 · DOI · Paper page
- Dankner, 2009, Treatment of stable atrial fibrillation in the emergency department: a population-based comparison of electrical direct-current versus pharmacological cardioversion or conservative management, Cardiology, 112, 270, 10.1159/000151703 · DOI
- Lown, 1967, Electrical reversion of cardiac arrhythmias, Br Heart J, 29, 469, 10.1136/hrt.29.4.469 · DOI
- Crijns, 2014, Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study, Int J Cardiol, 172, 588, 10.1016/j.ijcard.2014.01.099 · DOI
- Stiell, 2011, Variation in management of recent-onset atrial fibrillation and flutter among academic hospital emergency departments, Ann Emerg Med, 57, 13, 10.1016/j.annemergmed.2010.07.005 · DOI
- Hindricks, 2021, Eur Heart J, 42, 373, 10.1093/eurheartj/ehaa612 · DOI
- Hernandez-Madrid, 2013, Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey, Europace, 15, 915, 10.1093/europace/eut143 · DOI
- Pisters, 2012, Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey, Europace, 14, 666, 10.1093/europace/eur406 · DOI
- Brandes, 2020, Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure, Europace, 22, 1149, 10.1093/europace/euaa057 · DOI
- Dankner, 2009, Treatment of stable atrial fibrillation in the emergency department: a population-based comparison of electrical direct-current versus pharmacological cardioversion or conservative management, Cardiology, 112, 270, 10.1159/000151703 · DOI
- Oral, 1999, Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment, N Engl J Med, 340, 1849, 10.1056/NEJM199906173402401 · DOI
- Pedersen, 2001, Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) substudy, Circulation, 104, 292, 10.1161/01.CIR.104.3.292 · DOI · Paper page
- Deedwania, 1998, Circulation, 98, 2574, 10.1161/01.CIR.98.23.2574 · DOI
- Brembilla-Perrot, 2001, Predictors of atrial flutter with 1:1 conduction in patients treated with class I antiarrhythmic drugs for atrial tachyarrhythmias, Int J Cardiol, 80, 7, 10.1016/S0167-5273(01)00459-4 · DOI
- Singh, 2000, Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study, Circulation, 102, 2385, 10.1161/01.CIR.102.19.2385 · DOI · Paper page
- Singh, 2005, Amiodarone versus sotalol for atrial fibrillation, N Engl J Med, 352, 1861, 10.1056/NEJMoa041705 · DOI · Paper page
- Kober, 2008, Increased mortality after dronedarone therapy for severe heart failure, N Engl J Med, 358, 2678, 10.1056/NEJMoa0800456 · DOI
- Singh, 2000, Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study, Circulation, 102, 2385, 10.1161/01.CIR.102.19.2385 · DOI · Paper page
- Abraham, 2015, Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter, Circ Arrhythm Electrophysiol, 8, 772, 10.1161/CIRCEP.114.002339 · DOI
- Pedersen, 2001, Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy, Circulation, 104, 292, 10.1161/01.CIR.104.3.292 · DOI · Paper page
- Alboni, 2004, Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach, N Engl J Med, 351, 2384, 10.1056/NEJMoa041233 · DOI · Paper page
- Andrade, 2018, Clinical effectiveness of a systematic "pill-in-the-pocket" approach for the management of paroxysmal atrial fibrillation, Heart Rhythm, 15, 9, 10.1016/j.hrthm.2017.10.002 · DOI
- Azpitarte, 1997, Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study, Eur Heart J, 18, 1649, 10.1093/oxfordjournals.eurheartj.a015146 · DOI
- Markman, 2022, Safety of pill-in-the-pocket class 1C antiarrhythmic drugs for atrial fibrillation, J Am Coll Cardiol EP, 8, 1515
- Singh, 2005, Amiodarone versus sotalol for atrial fibrillation, N Engl J Med, 352, 1861, 10.1056/NEJMoa041705 · DOI · Paper page
- Hamilton, 2020, Amiodarone: a comprehensive guide for clinicians, Am J Cardiovasc Drugs, 20, 549, 10.1007/s40256-020-00401-5 · DOI
- Tisdale, 2020, Drug-induced arrhythmias: a scientific statement from the American Heart Association, Circulation, 142, e214, 10.1161/CIR.0000000000000905 · DOI
- Singh, 2000, Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study, Circulation, 102, 2385, 10.1161/01.CIR.102.19.2385 · DOI · Paper page
- Torp-Pedersen, 1999, Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group, N Engl J Med, 341, 857, 10.1056/NEJM199909163411201 · DOI
- Ellenbogen, 1996, Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study, J Am Coll Cardiol, 28, 130, 10.1016/0735-1097(96)00121-0 · DOI
- Stambler, 1996, Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators, Circulation, 94, 1613, 10.1161/01.CIR.94.7.1613 · DOI
- Vardas, 2000, Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study, Chest, 117, 1538, 10.1378/chest.117.6.1538 · DOI
- Kochiadakis, 1998, Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion, Cardiovasc Drugs Ther, 12, 75, 10.1023/A:1007714203984 · DOI
- Stambler, 1997, Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy, Circulation, 96, 4298, 10.1161/01.CIR.96.12.4298 · DOI · Paper page
- Singh, 2005, Amiodarone versus sotalol for atrial fibrillation, N Engl J Med, 352, 1861, 10.1056/NEJMoa041705 · DOI · Paper page
- Neefs, 2017, Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis, Int J Cardiol, 231, 155, 10.1016/j.ijcard.2016.12.029 · DOI · Paper page
- Kowey, 2010, Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial, JAMA, 304, 2363, 10.1001/jama.2010.1735 · DOI · Paper page
- Gencer, 2021, Effect of long-term marine -3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis, Circulation, 144, 1981, 10.1161/CIRCULATIONAHA.121.055654 · DOI · Paper page
- Andrade, 2021, Cryoablation or drug therapy for initial treatment of atrial fibrillation, N Engl J Med, 384, 305, 10.1056/NEJMoa2029980 · DOI
- Pérez, 2009, Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis, Circ Arrhythm Electrophysiol, 2, 393, 10.1161/CIRCEP.109.871665 · DOI
- Disertori, 2011, Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial, Am Heart J, 162, 382, 10.1016/j.ahj.2011.05.008 · DOI
- Senoo, 2014, Progression to the persistent form in asymptomatic paroxysmal atrial fibrillation, Circ J, 78, 1121, 10.1253/circj.CJ-13-1272 · DOI
- Yang, 2021, Associations of atrial fibrillation progression with clinical risk factors and clinical prognosis: a report from the Chinese Atrial Fibrillation Registry study, J Cardiovasc Electrophysiol, 32, 333, 10.1111/jce.14826 · DOI
- Holmqvist, 2015, Heart rate is associated with progression of atrial fibrillation, independent of rhythm, Heart, 101, 894, 10.1136/heartjnl-2014-307043 · DOI
- January, 2014, 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, J Am Coll Cardiol, 64, e1, 10.1016/j.jacc.2014.03.022 · DOI · Paper page
- Mark, 2019, Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1275, 10.1001/jama.2019.0692 · DOI
- Miura, 2020, Treatment strategies and subsequent changes in the patient-reported quality-of-life among elderly patients with atrial fibrillation, Am Heart J, 222, 83, 10.1016/j.ahj.2020.01.011 · DOI
- Willems, 2022, Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial, Eur Heart J, 43, 1219, 10.1093/eurheartj/ehab593 · DOI
- Packer, 2019, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1261, 10.1001/jama.2019.0693 · DOI
- Kirchhof, 2020, Early rhythm-control therapy in patients with atrial fibrillation, N Engl J Med, 383, 1305, 10.1056/NEJMoa2019422 · DOI
- Chew, 2022, Diagnosis-to-ablation time predicts recurrent atrial fibrillation and rehospitalization following catheter ablation, Heart Rhythm O2, 3, 23, 10.1016/j.hroo.2021.11.012 · DOI
- Di Biase, 2016, Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial, Circulation, 133, 1637, 10.1161/CIRCULATIONAHA.115.019406 · DOI
- Marrouche, 2018, Catheter ablation for atrial fibrillation with heart failure, N Engl J Med, 378, 417, 10.1056/NEJMoa1707855 · DOI
- Di Biase, 2010, Left atrial appendage: an underrecognized trigger site of atrial fibrillation, Circulation, 122, 109, 10.1161/CIRCULATIONAHA.109.928903 · DOI
- Calkins, 2017, 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation, Heart Rhythm, 14, e275, 10.1016/j.hrthm.2017.05.012 · DOI
- Packer, 2019, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1261, 10.1001/jama.2019.0693 · DOI
- Calkins, 2009, Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses, Circ Arrhythm Electrophysiol, 2, 349, 10.1161/CIRCEP.108.824789 · DOI · Paper page
- Blomström-Lundqvist, 2019, Effect of Catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial, JAMA, 321, 1059, 10.1001/jama.2019.0335 · DOI
- Packer, 2013, Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial, J Am Coll Cardiol, 61, 1713, 10.1016/j.jacc.2012.11.064 · DOI
- Jais, 2008, Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study, Circulation, 118, 2498, 10.1161/CIRCULATIONAHA.108.772582 · DOI
- Reynolds, 2018, A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial, J Am Coll Cardiol EP, 4, 580
- Packer, 2019, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1261, 10.1001/jama.2019.0693 · DOI
- Steinberg, 2015, Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial, Eur Heart J, 36, 288, 10.1093/eurheartj/ehu359 · DOI
- Al-Khatib, 2013, Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial, Eur Heart J, 34, 2464, 10.1093/eurheartj/eht135 · DOI
- Marrouche, 2018, Catheter ablation for atrial fibrillation with heart failure, N Engl J Med, 378, 417, 10.1056/NEJMoa1707855 · DOI
- Piccini, 2012, Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation, Circulation, 126, 2200, 10.1161/CIRCULATIONAHA.112.109330 · DOI
- Calkins, 2017, 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation, Heart Rhythm, 14, e275, 10.1016/j.hrthm.2017.05.012 · DOI
- Campbell, 2020, Sex-based differences in procedural complications associated with atrial fibrillation catheter ablation: a systematic review and meta-analysis, J Cardiovasc Electrophysiol, 31, 3176, 10.1111/jce.14758 · DOI
- Russo, 2021, Association between sex and treatment outcomes of atrial fibrillation ablation versus drug therapy: results from the CABANA trial, Circulation, 143, 661, 10.1161/CIRCULATIONAHA.120.051558 · DOI
- Noseworthy, 2015, Patterns of anticoagulation use and cardioembolic risk after catheter ablation for atrial fibrillation, J Am Heart Assoc, 4
- Santhanakrishnan, 2016, Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction, Circulation, 133, 484, 10.1161/CIRCULATIONAHA.115.018614 · DOI
- Rillig, 2021, Early rhythm control therapy in patients with atrial fibrillation and heart failure, Circulation, 144, 845, 10.1161/CIRCULATIONAHA.121.056323 · DOI
- Di Biase, 2016, Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial, Circulation, 133, 1637, 10.1161/CIRCULATIONAHA.115.019406 · DOI
- MacDonald, 2011, Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial, Heart, 97, 740, 10.1136/hrt.2010.207340 · DOI
- Marrouche, 2018, Catheter ablation for atrial fibrillation with heart failure, N Engl J Med, 378, 417, 10.1056/NEJMoa1707855 · DOI
- Parkash, 2022, Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial, Circulation, 145, 1693, 10.1161/CIRCULATIONAHA.121.057095 · DOI
- Turagam, 2019, Catheter ablation of atrial fibrillation in patients with heart failure: a meta-analysis of randomized controlled trials, Ann Intern Med, 170, 41, 10.7326/M18-0992 · DOI
- Packer, 2021, Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial, Circulation, 143, 1377, 10.1161/CIRCULATIONAHA.120.050991 · DOI
- Khand, 2003, Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?, J Am Coll Cardiol, 42, 1944, 10.1016/j.jacc.2003.07.020 · DOI · Paper page
- Kotecha, 2020, Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial, JAMA, 324, 2497, 10.1001/jama.2020.23138 · DOI
- Clemo, 1998, Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias, Am J Cardiol, 81, 594, 10.1016/S0002-9149(97)00962-4 · DOI
- Delle Karth, 2001, Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias, Crit Care Med, 29, 1149, 10.1097/00003246-200106000-00011 · DOI
- Brignole, 1998, Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study, Circulation, 98, 953, 10.1161/01.CIR.98.10.953 · DOI
- Kay, 1998, The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators, J Interv Card Electrophysiol, 2, 121, 10.1023/A:1009795330454 · DOI
- Weerasooriya, 2003, The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT), J Am Coll Cardiol, 41, 1697, 10.1016/S0735-1097(03)00338-3 · DOI
- Nerheim, 2004, Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia, Circulation, 110, 247, 10.1161/01.CIR.0000135472.28234.CC · DOI
- Roy, 2008, Rhythm control versus rate control for atrial fibrillation and heart failure, N Engl J Med, 358, 2667, 10.1056/NEJMoa0708789 · DOI · Paper page
- Van Gelder, 2010, Lenient versus strict rate control in patients with atrial fibrillation, N Engl J Med, 362, 1363, 10.1056/NEJMoa1001337 · DOI · Paper page
200 of 246 shown
Cited by
Sorted by citations
Items 601–700 of 933
Alamri, Y., Sundermann, M., O'Mahony, A., Hiskett, I., Zhang, M., Neal, C., & Chin, P. K. L. (2025) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001361
QT Prolongation and Ventricular Pre-Excitation in Psychiatric Illness
Irwin, H., Downey, M. C., BUDA, K. G., Simegn, M. A., & Karim, R. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.104127
Educational Attainment as a Causal and Modifiable Risk Factor for Atrial Fibrillation
Otsuka, N., & Okumura, Y. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.05.018
Cardio-Embolic Stroke in a 14-Year-Old Boy Due to SCN5A-Associated Atrial Standstill
Bahbah, A., Sengupta, J. N., Kelly, M., Bade, E., Witt, D., Gornick, C. C., Cavalcante, J. L., & Zakaib, J. S. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.104144
Essa, H., Balu, A., Amanullah, Y., Duvva, D., Burhan, H., Frost, F. J., Manuel, A. R., Welters, I. D., & Lip, G. Y. H. (2025) · ERJ Open Research · doi:10.1183/23120541.00605-2025
Sterpetti, A. V., Miceli, F., Girolamo, A. D., Iannone, I., Sapienza, P., & di Marzo, L. (2025) · Angiology · doi:10.1177/00033197251356583
Prosperi‐Porta, G., Al-Abcha, A. K., Simard, T., Hibbert, B. M., & Abdel‐Razek, O. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2543184
Zhang, M., Singh, R., Dhuliawala, S., Stafkey-Mailey, D., Vodicka, E. L., Cheng, D., Dubey, A., & Hagan, M. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0057
Khaleel, I. M., Jawad, W. I., Gauri, A. J., Burgess, A., & McNamara, D. A. (2025) · CASE · doi:10.1016/j.case.2025.06.006
Kim, K., Hwang, Y. M., Choi, S.-S., Lee, H., Son, Y.-J., & Yoo, M. (2025) · Life · doi:10.3390/life15081298
Bridging the Gap Between Atrial Fibrillation, Cardiomyopathy and Prognosis
Hammersley, D. J., McDonagh, T. A., & Prasad, S. K. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.007
Beyond Tachycardia-Induced Cardiomyopathy
Kong, A., Bernardes, T., Kaso, E. R., Ramirez, A., & Carlan, S. J. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.105302
Ren, Y., Zhang, H., & Tian, Y. (2025) · Frontiers in Surgery · doi:10.3389/fsurg.2025.1653123
Tanacli, R., Heil, E., Böck, M., Dagres, N., Asatryan, B., Bartels, F., Falk, V., Hindricks, G., Gerds‐Li, J., Kelle, S., et al. (2025) · medRxiv · doi:10.1101/2025.09.21.25336292
Dai, Z., Liu, Y., Huang, X., Jiang, Z., Wu, W., Wang, Z., Yang, Y., Dong, F., & Huang, L. (2025) · Research Square · doi:10.21203/rs.3.rs-7295399/v1
Zheng, Y., Liu, Y., Zheng, X., Tse, G., Lip, G. Y. H., Chen, K., & Liu, T. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf163
Sun, H., Hu, S. T., Pan, R., Zhuang, Q., & Zheng, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1472183
Naveed, D., Ullah, I., Khan, A., Khan, M. G., Ghufran, M. H., Shah, M. H., Ahmad, W., Usman, H., & Ullah, N. (2025) · Cureus · doi:10.7759/cureus.93982
Impact of Substantial Weight Loss on Digoxin Intoxication During Long-term Therapy
Nakayama, H., Shiga, T., & Tanaka, M. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251369114
Postoperative atrial fibrillation after cardiac surgery: what is new?
Lee, J. G., & Ha, A. C. T. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001262
Fauchier, L., Lochon, L., & Lip, G. Y. H. (2025) · Circulation · doi:10.1161/circulationaha.125.074611
Brembilla-Perrot, B. (2025) · EMC - Cardiologie · doi:10.1016/s1166-4568(24)48553-7
Ding, R., Su, R., Liu, J., Cai, S., & Zhao, H. (2025) · Research Square · doi:10.21203/rs.3.rs-7534396/v1
Lai, B., Ziser, K. E. D., Appay, M., Potts, C., & Livori, A. (2025) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.70043
Paving the Way to a Radiation-Free Era
Choi, E., & Ryu, H. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.08.023
Djuranovic, A., Ristić, J., Antić, M., Rajović, N., Mirkovic, M., Batinic, D., Maletic, M., Kizilkilic, S. E., Ferrara, V. Z., Prodanović, V., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217466
Zenjaya, K. T., Rosyadi, R. N., Mulyadi, A., & Iswara, I. D. G. N. D. (2025) · The Egyptian Heart Journal · doi:10.1186/s43044-025-00697-1
Surgical Reintervention for Complex, Multivalvular Rheumatic Heart Disease
Khan, K. R., Burke, C. R., & Steiner, J. M. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.104356
Ghazal, M., Shaikh, S., Daniel, Z., Daghstani, O., Musumeci, J., Gajjala, A., Beegle, S. H., & Torosoff, M. T. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.10.017
Utility of Screening for Atrial Fibrillation in Older Patients to Prevent Thromboembolic Phenomena
DOMANSKI, M. J., Dickfeld, T.-M. L., & Wu, C. O. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1581
Cryoballoon Ablation in Older Patients With Heart Failure
Miyazawa, H., Yanagisawa, S., Suzuki, H., Yoshida, Y., Morishima, I., Kanzaki, Y., Ishikawa, S., Kamikubo, Y., Kato, H., Mizutani, Y., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102244
Marjamaa, A., Karvonen, J., Räsänen, J. V., Suominen, S. H. H., Aro, A. L., & Raatikainen, P. M. J. (2025) · HeartRhythm Case Reports · doi:10.1016/j.hrcr.2025.10.031
Pre–arrest oral anticoagulants’ impact on cardiac arrest mortality: MIMIC–IV cohort retrospect
Nie, X., He, L., & Zheng, X. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1599318
Lusk, J. B., Nalawade, V. V., Wilson, L. E., Yarnell, S. C., Song, A., Schrag, M., Poli, S., Hammill, B. G., Li, F., & Grory, B. M. (2025) · Journal of Internal Medicine · doi:10.1111/joim.70041
Prevalence of Undiagnosed OSA in Patients With All Patterns of Atrial Fibrillation
Mills, E. W., Im, K., Sofer, T., Shea, J. B., Tadros, T. M., Zei, P. C., Sauer, W. H., Martin, D. T., Antman, E. M., & Javaheri, S. (2025) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2025.09.027
Mdaihly, M., Motairek, I. K., Younis, A., Tabaja, C., Demian, J., Watfa, A., Besir, B., Hussein, A. A., Taigen, T. L., Bhargava, M., et al. (2025) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.70089
Self-citationDai, W., Yang, Z., Li, S., Li, M., Jiang, C., Zhou, N., Sang, C., Long, D., Du, X., Dong, J., et al. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05283-6
Antiarrhythmic Drug Therapy for Acute Management of Atrial Fibrillation and Atrial Flutter
Habibi, M., Rahim, M. A., & Mittal, S. (2025) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2025.10.003
Chen, L., Du, X., Liu, J., Cui, C., Lü, P., Du, M., Yang, Y., Zhang, C., & Chen, W. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.134036
Self-citationSawalha, K., Alamat, L., Rana, A., Bruich, L., & Candales, A. L. (2025) · Cureus · doi:10.7759/cureus.97446
Social Determinants of Health in Atrial Fibrillation Care
Cheung, C. C., & Kalman, J. M. (2025) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2025.09.033
Clinical Trials on Atrial Fibrillation in Asia
Kong, X., Yang, Z., & Ma, C. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.09.005
Anticoagulation Update: Safe Management Strategies for the Perianesthesia Nurse
Pal, A. D. (2025) · Journal of PeriAnesthesia Nursing · doi:10.1016/j.jopan.2025.09.001
Open wide: a fresh look at periodontitis and atrial fibrillation
Haimovich, J. S., Paras, M. L., & Khurshid, S. S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf762
Pham, T. H., Kamath, A. R., Rogers, J. H., Smith, T. W., Aman, E. A., Andrews, R., & Singh, G. D. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.106403
Candeloro, M., Chen, Q., Ehrlinder, H. F. M., & Gigante, B. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06733-8
Berrajaa, M., Jaouhari, H., Beladel, W., Elbaz, K. A., & Minaoui, M. E. (2025) · Cureus · doi:10.7759/cureus.98986
TERASHIMA, R., Enomoto, Y., Hirai, R., Hara, H., & Hiroi, Y. (2025) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytaf639
Does Digital Screening for Atrial Fibrillation Reach its Target Group?
Freyer, L., Spielbichler, P., Tenbrink, L., Sierra, L. E. V., Vogl, M. F., Korovesis, T., Klemm, M., Maßberg, S., Bauer, A., & Rizas, K. D. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102416
Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation
Ghosh, S., & Darden, D. J. (2025) · JAMA · doi:10.1001/jama.2025.20810
Horowitz, H., Amsalem, I., Carasso, S., Postell, Y. Y., Karmi, M., Asher, E., Rav-Acha, M., Glikson, M., Bruoha, S., & Shuvy, M. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.134095
de Pontes, V. B., Carvalho, P. E. P., Felix, N. S., Nogueira, A., Clemente, M. R. C., Gastaldelo, V., Preda, A., & Garot, P. (2025) · Journal of Cardiology · doi:10.1016/j.jjcc.2025.12.004
Catheter Ablation for Ischemic Ventricular Tachycardia
Dixit, S., & Frankel, D. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.10.075
Jia, S., Yin, Y., Mou, X., Zheng, J., Li, Z., Hu, T., Zhao, J., Lin, J., Song, J., Cheng, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25556537
Anticoagulation for Atrial Fibrillation or Atrial Flutter
Lee, J. P. (2025) · Springer eBooks · doi:10.1007/978-3-032-07080-7_4
Alternating Bundle Branch Block Associated with Atrial Fibrillation: A Rare Clinical Entity
Sitharthan, M., Bhushan, D., & Kumar, S. (2025) · doi:10.5005/apijcr-11050-0005
Advances in Antiarrhythmic Drug Therapy
Olleik, F., & Kowey, P. R. (2025) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2025.10.006
Zero-fluoroscopy left atrial appendage occlusion with the Watchman FLX device
Chakravarty, T., Skaf, S., Singh, U., Garg, T., Gandhi, N., Malik, V., Makar, M., Gupta, A., Berman, D. S., Friedman, J., et al. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.12.028
Chen, P., Yin, X., & Ren, L. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05350-y
Tomura, N., Senoo, K., Nishimura, T., Tanaka, E., Hadase, M., Shimooka, N., & Matoba, S. (2025) · Heart Rhythm O2 · doi:10.1016/j.hroo.2025.12.014
Opone, E., Khan, N., & Jabeen, S. (2025) · Cureus · doi:10.7759/cureus.100284
Subclinical Atrial Fibrillation Prediction in Patients with CIED by a Novel Deep Learning Framework
Lan, Y., Lin, C., Zhang, N., Cao, Q., Jin, Q., Luo, Q., Yue, W., Bao, Y., Lin, C., Pan, W., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13010018
Dağaşan, T., Dağaşan, G., Mervegül, K. A. Y. A., Minnet, M., & Enginyurt, Ö. (2025) · Turkish Journal of Family Practice · doi:10.54308/turkjfampract.2025.861
Alhashimi, R. A. H., Alhilfi, H. S. Q., & Mohammed, T. T. (2025) · Кардиология в Беларуси · doi:10.34883/pi.2025.17.6.007
Closing the Appendage, Opening Questions
Gala, A. R. P. B. E., & Roten, L. (2026) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2025.11.022
Siao, W.-Z., Wang, W.-Y., Huang, J., Wei, J. C., Yang, T., & Jong, G. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e44509
Natale, A., Mohanty, S., Andrade, J. G., & MANSOUR, M. C. (2026) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2025.12.024
Self-citationImpacts of atrial fibrillation and surgical ablation on rheumatic and degenerative mitral surgeries
Park, T. H., Kim, K., Kang, S. R., Ku, M. J., Kim, H. R., Kim, H. J., Yoo, J. S., Jung, S., Chung, C. H., & Kim, J. B. (2026) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2025.12.033
Wang, Y., Tsai, C., Chua, S., Huang, P., Chen, J., Chiu, F., Hwang, J., & Wang, C.-H. (2026) · Thrombosis and Haemostasis · doi:10.1055/a-2760-8134
Kwon, S. I., Ahn, H., Nam, J. H., Kwon, S., Lee, S., Choi, E., & Lee, E. B. N. (2026) · Scientific Reports · doi:10.1038/s41598-026-35628-w
Kinjo, T., Kimura, M., Toyama, Y., Nishizaki, K., & Tomita, H. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2025.106738
Terms used to characterize the course of chronic heart failure: are all the points on the board?
Kalyuzhin, V. V., Teplyakov, A. T., Bespalova, I. D., Kalyuzhinа, E. V., Chernogoryuk, G. E., Terentyeva, N. N., Garganeeva, N. P., Сибирева, О. Ф., Usov, V. Y., Timofeeva, K. S., et al. (2026) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2025-4-132-142
Sex-specific impact of body mass index on recurrence of atrial fibrillation after catheter ablation
Özcan, C., Deshmukh, A., Aziz, Z. A., Mayer, M., Kassem, H. A., Treger, J. S., Yeshwant, S. C., Beaser, A. D., Upadhyay, G., Huang, H., et al. (2026) · Heart Rhythm O2 · doi:10.1016/j.hroo.2026.01.024
Postoperative Management of Patients Undergoing Coronary Artery Bypass Grafting
Awad, A. K., Abhishek, S., Tang, A., Alshneikat, M., Koprivanac, M. J., Elgharably, H., Tong, M. Z. Y., Unai, S., Soltesz, E. G., Adi, A. M., et al. (2026) · The Heart Surgery Forum · doi:10.31083/hsf50271
A rare case report of dextrocardia combined with atrial fibrillation and ischemic bowel disease
Zhao, Y., Li, J., Guo, Z., & Zhang, X. (2026) · Medicine · doi:10.1097/md.0000000000047189
Javaheri, S., McKane, S. W., & Germany, R. E. (2026) · Sleep Medicine · doi:10.1016/j.sleep.2026.108824
Nakano, T., Okayama, K., Yasuoka, M., Shigeta, H., Kawamura, A., Sekihara, T., Ozu, K., Oka, T., Seno, S., & Sakata, Y. (2026) · doi:10.2196/preprints.91960
Comparative analysis of Chinese large language model performance on atrial fibrillation questions
Liu, G., Cheng, K., Xu, Y., Pang, Y., Ling, Y., Chen, Q., Zhu, W., & Junbo, G. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05566-6
Li, S., Zhang, Y., Wu, W., Li, G., Huang, T., Zeng, K., Tong, C., Li, H., & Huang, H. (2026) · BioData Mining · doi:10.1186/s13040-026-00525-5
Kim, D., Kim, Y., Lee, S. B., Kang, J., & Park, J. (2026) · Heart Rhythm O2 · doi:10.1016/j.hroo.2026.02.002
Wu, Y., Wei, L., Wang, F., Yang, X., Zhao, M., He, M., Xu, J., Li, Y., & Sun, J. (2026) · Lecture notes in electrical engineering · doi:10.1007/978-981-95-6841-3_7
Conserved RNA–protein modules link early anthracycline responses to atrial fibrillation riskPreprint
Johnson, O. D., Matthews, E. R., Paul, S., Gutiérrez, J. A., Russell, W. K., & Ward, M. C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.15.706019
Bobyleva, T. A., Tkachenko, S. B., Казаков, С. П., & Борисович, П. С. (2026) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2025-103-10-11-753-759
Pseudo-Migration After Left Atrial Appendage Occlusion
Delgado, P. J. D., Katapadi, A., Kabra, R., Kumbar, C., & Lakkireddy, D. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2025.106559
Shared Neurocardiac Pathways Linking Atrial Fibrillation and Depression: A UK Biobank AnalysisPreprint
Verdonk, C., Talishinsky, A., Hakimi, N., Misaki, M., Steinhäuser, J. L., Thompson, W. K., Fan, C. C., Paulus, M. P., Ajijola, O. A., & Khalsa, S. S. (2026) · medRxiv · doi:10.64898/2026.02.21.26346796
Ran, Y., zhang, Y., Cai, Y., & 刘海林 (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1765791
AlShammary, S., Alotaibi, N. E., Alharbi, R. S., Aljohani, R. M., Alotaibi, B., Suliman, I. F., & Ibrahim, S. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s575840
Less Is More: A Case of Delayed Return of Normal Conduction
Gorantla, A., Panduranga, V. T., Richard, S., Cali, F., & Graham-Hill, S. (2026) · Cureus · doi:10.7759/cureus.104443
Magno, J. D. A., Jose, G. R. B., & Monteblanco, C. D. P. (2026) · BMJ Case Reports · doi:10.1136/bcr-2025-269530
Sex-Based Differences in Clinical Outcomes With Edoxaban Therapy
Kim, G.-H., Cho, M., Kim, S., Kang, D., Ahn, J., Oh, Y., Lee, C. H., Choi, E., Lee, J. H., Kwon, C. H., et al. (2026) · JACC Asia · doi:10.1016/j.jacasi.2025.12.022
Rossi, M., Bucci, T., Tartaglia, E., Askarinejad, A., Lam, S. H. M., Rigutini, A. G., Ferri, C., Boriani, G., Tse, H.-F. T., Chao, T., et al. (2026) · EP Europace · doi:10.1093/europace/euag032 · Cited by 1
Drugs Don't Work in Patients Who Don't Take Them
Cho, M. S. (2026) · JACC Asia · doi:10.1016/j.jacasi.2025.12.003
Sakai, M., Higuchi, S., Matsui, Y., Hasegawa, S., Kataoka, S., Yazaki, K., Kikuchi, K., Watanabe, S., Kani, K., Takefuta, K., et al. (2026) · JACC: Asia · doi:10.1016/j.jacasi.2025.12.013
Pérez, D. B., Urbistondo, C. M., & de Jalón, P. I. G. (2026) · Actualización en Medicina de Familia · doi:10.55783/amf.220202
Faheem, M. S. B., Cheema, S., Khan, A. A., Hassan, S. T., Fatima, S. T., & Samadi, S. (2026) · European journal of medical research · doi:10.1186/s40001-026-04139-9
Isakadze, N., & SPRAGG, D. D. (2026) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2026.01.029
Shi, C., Wang, X., Zhang, S., Guo, R., & Wu, T. Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1777780
Huang, B., Chen, Y., Liu, Y., Lam, H. M., Ishiguchi, H., Chao, T., Huisman, M. V., Olshansky, B., & Lip, G. Y. H. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04301-5
Lu, T., Wang, G., Zhang, S., Qin, Y., Guo, Z., & Bai, Y. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.107254
Xie, H., Yin, J., Lu, J., Jiang, Y., Chen, L., Yao, Y., & Liu, J. (2026) · HeartRhythm Case Reports · doi:10.1016/j.hrcr.2026.03.002
Self-citation
Metadata
- Authors
- Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., Linta, K. T., Marcus, G. M., McCarthy, P. M., Patel, N., Patton, K. K., Perez, M. V., Piccini, J. P., Russo, A. M., Sanders, P., Streur, M. M., Thomas, K. L., Times, S., Tisdale, J. E., Valente, A. M., Van Wagoner, D. R., Krahn, A. D., Andrade, J. G., Beavers, C. J., Bischoff, J. M., Bunch, T. J., Campbell, K. B., Chen, L. Y., Dharia, R., Dorsch, M. P., Gerstenfeld, E. P., Jones, A. E., Kaluzna, S. D., Masha, L., Nault, I., Noseworthy, P. A., Pellegrini, C. N., Tzeis, S. E., Volgman, A. S., & Zeitler, E. P.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Cleveland Clinic Lerner College of Medicine (US)
- University of Health Sciences and Pharmacy (US)
- Boston University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Temple University Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Wisconsin–Madison (US)
- University of Louisville (US)
- Denver VA Medical Center (US)
- Stanford Medicine (US)
- Columbia University Irving Medical Center (US)
- University of Arizona (US)
- West Virginia University (US)
- Mayo Clinic (US)
- University of California, San Francisco (US)
- Northwestern Medicine (US)
- University of Washington (US)
- Stanford University (US)
- Duke University (US)
- Royal Adelaide Hospital (AU)
- American College of Cardiology (US)
- Indiana University School of Medicine (US)
- Brigham and Women's Hospital (US)
- ORCID
- Joglar, José A.
- Chung, Mina K.
- Armbruster, Anastasia L.
- Benjamin, Emelia J.
- Chyou, Janice Y.
- Cronin, Edmond M.
- Deswal, Anita
- Eckhardt, Lee L.
- Goldberger, Zachary D.
- Gopinathannair, Rakesh
- Hess, Paul L.
- Hlatky, Mark
- Ibeh, Chinwe
- Indik, Julia H.
- Kido, Kazuhiko
- Kusumoto, Fred
- Link, Mark S.
- Marcus, Gregory M.
- McCarthy, Patrick M.
- Patel, Nimesh
- Patton, Kristen K.
- Perez, Marco V.
- Piccini, Jonathan P.
- Russo, Andrea M.
- Sanders, Prashanthan
- Streur, Megan M.
- Thomas, Kevin L.
- Tisdale, James E.
- Valente, Anne Marie
- Krahn, Andrew D.
- Andrade, Jason G.
- Beavers, Craig J.
- Bunch, T. Jared
- Campbell, Kristen Bova
- Chen, Lin Yee
- Dharia, Robin
- Dorsch, Michael P.
- Jones, Aubrey E.
- Kaluzna, Stephanie Dwyer
- Masha, Luke
- Nault, Isabelle
- Noseworthy, Peter A.
- Pellegrini, Cara N.
- Tzeis, Stylianos E.
- Volgman, Annabelle Santos
- Zeitler, Emily P.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2024-01
- Volume
- 83
- Issue
- 1
- Pages
- 109-279
- ISSN
- 0735-1097 (ISSN-L)
- PMC
- PMC11104284
- OpenAlex
- W4389165660
- Semantic Scholar
- 6b9e178eb1680000a7b88c27e8b90f736019ac3f
- Cited by
- 933
- References
- 1,396
- Citations by year
- 2026: 383 · 2025: 336 · 2024: 213
- FWCI
- 183.62
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc)
- Funders
- U.S. Department of Veterans Affairs (IK6 BX006185)
- National Heart, Lung, and Blood Institute (R01HL158071, P01HL158502)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Keywords
- atrial fibrillation, diagnosis, management, thromboembolic risk assessment, anticoagulation, left atrial appendage closure, catheter ablation, surgical ablation, risk factor control, atrial fibrillation prevention, cardiac arrhythmias
- MeSH terms
- American Heart Association, Atrial Fibrillation, Cardiology, Humans, Risk Factors, Thromboembolism, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
